Company Analysis
Sign in

Humacyte, Inc. (HUMA)

Nasdaq: HUMA · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 2020
Full chart Alerts Compare
Grade3.9
◀ Past 4.2● Present 3.2▶ Future 4.3
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 27, 2026Mar 31, 2025Mar 28, 2024Mar 24, 2023Mar 29, 2022Feb 16, 2021
Revenue2,038,0000····
Cost of revenue9,702,0000····
Research and development69,302,00088,599,00076,550,00063,260,00061,341,00054,078,000
General and administrative31,171,00025,799,00023,497,00022,883,00021,130,00012,013,000
Total operating expenses·114,398,000100,047,00086,143,00082,471,00066,091,000
Total costs and expenses110,175,000114,398,000····
Operating income-108,137,000-114,398,000-100,047,000-84,578,000-81,208,000-64,600,000
Interest expense11,250,0009,277,0006,599,0006,200,0004,348,0002,202,000
Interest and investment income2,587,0004,104,0005,467,0002,629,00016,000278,000
Total non-operating income (expense)67,304,000-34,303,000-10,729,00072,613,00054,731,000-1,924,000
Income before income taxes-40,834,000·····
Income tax expense000000
Net income-40,833,000-148,701,000-110,776,000-11,965,000-26,477,000-66,524,000
Earnings per share, basic-0.26-1.26-1.07-0.12-0.66-11.54
Earnings per share, diluted-0.26-1.26-1.07-0.12-0.66-11.54
Weighted average shares, basic158,160,468118,479,097103,420,238103,051,36639,970,3985,765,688
Weighted average shares, diluted158,160,468118,479,097103,420,238103,051,36639,970,3985,765,688
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfGoodsAndServicesSold
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton HUMA · research, not advice